eLetters

322 e-Letters

  • What to conclude from the results of the LEGS study and what not?
    Andreas G. Helg

    Dear Editor,

    Like probably many others, we have been waiting eagerly for the results of the LEGS study (1). The expectation was that this trial would bring light into the ongoing controversy about the value of chondroitin, glucosamine, and their combination in the treatment of osteoarthritis (OA) of the knee, and provide answers to several open questions. The LEGS study fully met this expectation as to the structure-...

    Show More
  • Response to Dr Iannone's eLetter
    Martin Neovius

    Dear Editor,

    We thank Dr. Iannone et al for their comment on our recent study on drug survival on etanercept, infliximab and adalimumab in patients with RA.[1] They noted similarities between our findings and their previously published data[2] on 853 Italian patients starting TNF inhibitor treatment in 2003-2004 in terms of best drug survival on etanercept, similar 4- vs 5 -year drug survival for etanercept and infl...

    Show More
  • Is an extra dose of rituximab an efficacious and safe alternative to improve outcomes in rheumatoid arthritis? Comment on the article by Vital et al.
    Markus Bredemeier

    Dear Editor,

    I read with interest the paper by Vital el al. (1), a pilot study testing the efficacy of an extra dose of rituximab (completing 3x1000 mg over four weeks) in comparison to the standard-dose regimen (2x1000 mg) in rheumatoid arthritis (RA) patients with incomplete depletion of B cells after a first 1000 mg dose of RTX. The study represents an advance in the knowledge about the effects of rituximab, bu...

    Show More
  • Response to Dr Yazici's eLetter: Ethical issue of withholding treatment from patients with active rheumatoid arthritis
    Tsutomu Takeuchi

    Dear Editor,

    The ethical consideration in placebo-controlled studies of antirheumatic drugs is of primary importance. We thank Dr Yazici for his questions regarding the ethical aspect of our study.

    The GO-MONO study was designed to have placebo crossover to methotrexate (MTX) at Week 16, as a Registration Study to Japan Health Authority, following the MHLW Guideline for the Clinical Study and Evaluat...

    Show More
  • Diagnosing Erdheim-Chester Disease
    Lorenzo Dagna

    Dear Editor,

    Although we generally agree with Dr Juanos-Iborra et al [1] who noted that some of the most common manifestations of Erdheim-Chester disease (ECD) at time of onset (such as skeletal, constitutional or even neurological symptoms) may lack adequate specificity for a timely and prompt diagnosis, it is conceivable that the same manifestations, if unexplained, may often lead to further imaging and histologic...

    Show More
  • Response to 'In erosive hand osteoarthritis more inflammatory signs on ultrasound are found than in the rest of hand osteoarthritis' by Kortekaas et al
    Dr Ai Lyn Tan

    We read with interest the article 'In erosive hand osteoarthritis more inflammatory signs on ultrasound are found than in the rest of hand osteoarthritis' by Kortekaas et al [1]. The authors found that interphalangeal joints of erosive osteoarthritis (EOA) patients, with erosions being defined by conventional radiography (CR), demonstrated more sonographic inflammatory changes in adjacent non CR-eroded joints compared to...

    Show More
  • Comments on recent advances and recommendations for the assessment of autoantibodies to cellular antigens referred as anti-nuclear antibodies
    Michael Mahler

    Dear Editor,

    Despite significant efforts and advances in the field of autoimmune diagnostics, the standardization and proper use of antinuclear antibody (ANA) testing in clinical practice remains a challenge. In 2013, important contributions attempting to clarify and add rigor to this area have been published [1, 2]. In particular, the recent recommendations published by Agmon-Levin et al. [1] address very impo...

    Show More
  • Response to Gonzalez-Gay's eLetter on Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review
    Michael T Nurmohamed

    Dear Editor,

    In their comments about our systematic review on cardiovascular (CV) comorbidities in patients with psoriatic arthritis, (1) dr Gonzalez-Gay and colleagues, point out that in their studies, (2,3) in contrast to our Table 4, they did demonstrate a correlation between inflammatory parameters and flow-mediated dilatation (FMD) or intima media thickness (IMT). This is indeed correct when these tests are c...

    Show More
  • Re:Are autoantibodies to RNA-polymerase III to be incorporated in routine diagnostic laboratory algorithms for systemic autoimmune rheumatic diseases?
    Frank van den Hoogen

    Dear Editor

    In his letter, Jan Damoiseaux plees for testing of anti-RNA polymerase III antibodies (ARA), and also other (novel) SSc-associated antibodies, only for those patients who are really suspected for SSc. Damoiseaux argues that there is a necessity to provide clinical information together with the request for testing for rheumatic systemic autoimmune diseases.

    We very much agree that testing for S...

    Show More
  • Response
    Gianfranco Ferraccioli

    Dear Editor,

    We thank Aramugakani et al. for their critical reading of our Editorial (1) accompanying Cheng et al. paper on the role of long-lived plasma cells (PC) in driving murine lupus nephritis (LN) (2). First, we obviously share - and explicitely mentioned - the safety issues related to long-lived PC depletion, in particular a possible high infection rate. Second, our purpose was not to question the effe...

    Show More

Pages